晚期前列腺癌的选择性治疗降阶:我们是否已回到原点?
本文讨论转移性激素敏感性前列腺癌(mHSPC)早期治疗强化的证据背景下,治疗降阶的可行性。指出降阶证据有限,推荐用于老年或虚弱、体能状态差或出现显著毒性的患者;对PSA应答极佳或生物标志物有利者应个体化决策,权衡继续治疗的获益与长期副作用风险。
要点
- mHSPC早期治疗强化已有1级证据支持多药联合的生存获益。
- 降阶治疗证据有限,推荐用于老年或虚弱、体能状态差或显著毒性患者。
- PSA应答极佳或生物标志物有利者应个体化决策,可用风险分层工具。
核心结论
- mHSPC治疗降阶证据有限,推荐用于老年或虚弱、体能状态差或出现显著毒性的患者。
- 对PSA应答极佳或生物标志物有利的患者,应个体化决策,权衡继续治疗获益与长期副作用风险。
研究设计与样本
- 本文为综述,讨论mHSPC早期治疗强化与降阶的策略。
主要发现
- 关键试验为多药联合治疗mHSPC的生存获益提供了1级证据。
- 联合治疗的疗效不仅取决于如何强化治疗,也取决于如何降阶治疗。
关键数值与推荐
- 降阶治疗推荐用于老年或虚弱患者、体能状态差者或出现显著毒性者。
- 对PSA应答极佳或生物标志物有利的患者,决策应个体化,使用风险分层工具权衡继续治疗获益与长期副作用风险。
临床怎么用
- 对老年或虚弱、体能状态差或出现显著毒性的mHSPC患者,可考虑治疗降阶。
- 对PSA应答极佳或生物标志物有利的患者,应个体化决策,使用风险分层工具权衡继续治疗与长期副作用风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Compelling evidence has solidified the notion of early treatment intensification in managing patients with metastatic hormone-sensitive prostate cancer (mHSPC). Landmark trials have provided Level 1 evidence for the survival benefits achieved by combining multiple agents. The efficacy of combined therapy relies not only on how treatment is intensified but also on how it is de-escalated. This underscores the importance of tailored treatment approaches, potentially involving a reduction in therapy for specific patients, to strike a balance between the benefits of hormonal treatment and its associated adverse effects. While de-escalation of therapy in mHSPC remains challenging due to limited evidence, it is recommended for elderly or frail patients, those with poor performance status, or experiencing significant toxicity. However, for patients with excellent prostate-specific antigen responses or favourable biomarkers, decisions should be personalised, weighing the potential benefits of continued treatment against the risk of long-term side effects, using risk stratification tools where appropriate.
引用
- Chong B, Saad M, Chong TW, et al. Selective treatment de-escalation in advanced prostate cancer: have we come full circle? BJU Int. 2025. PMID: 39748463. doi:10.1111/bju.16632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。